GlycoMimetics Inc (GLYC) - Cash Flow Conversion Efficiency
Based on the latest financial reports, GlycoMimetics Inc (GLYC) has a cash flow conversion efficiency ratio of -1.513x as of March 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-5.11 Billion) by net assets ($3.38 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See GLYC days of operational coverage to measure how many days the company can operate on defensive assets alone.
GlycoMimetics Inc - Cash Flow Conversion Efficiency Trend (2011–2024)
This chart illustrates how GlycoMimetics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
GlycoMimetics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of GlycoMimetics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Taruga Minerals Ltd
AU:TAR
|
-0.126x |
|
Chitose Internasional Tbk
JK:CINT
|
-0.024x |
|
Skyline Investment S.A.
WAR:SKL
|
-0.002x |
|
Saga plc
LSE:SAGA
|
0.721x |
|
KINGFISH COMPANY EO -01
F:93G
|
N/A |
|
Eastern Technical Engineering Public Company Limited
BK:ETE
|
0.021x |
|
Xref Ltd
AU:XF1
|
0.137x |
|
TDH Holdings Inc
NASDAQ:PETZ
|
-0.067x |
Annual Cash Flow Conversion Efficiency for GlycoMimetics Inc (2011–2024)
The table below shows the annual cash flow conversion efficiency of GlycoMimetics Inc from 2011 to 2024. For the full company profile with market capitalisation and key ratios, see GLYC market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $5.31 Million | $-31.10 Million | -5.853x | -544.56% |
| 2023-12-31 | $38.41 Million | $-34.88 Million | -0.908x | +16.10% |
| 2022-12-31 | $42.93 Million | $-46.46 Million | -1.082x | -53.61% |
| 2021-12-31 | $81.60 Million | $-57.49 Million | -0.704x | -130.19% |
| 2020-12-31 | $128.22 Million | $-39.24 Million | -0.306x | +9.21% |
| 2019-12-31 | $154.20 Million | $-51.98 Million | -0.337x | -59.85% |
| 2018-12-31 | $205.46 Million | $-43.33 Million | -0.211x | +15.20% |
| 2017-12-31 | $119.70 Million | $-29.77 Million | -0.249x | +70.47% |
| 2016-12-31 | $35.30 Million | $-29.73 Million | -0.842x | -313.57% |
| 2015-12-31 | $40.47 Million | $-8.24 Million | -0.204x | -141.64% |
| 2014-12-31 | $50.80 Million | $-4.28 Million | -0.084x | +98.42% |
| 2013-12-31 | $2.91 Million | $-15.54 Million | -5.345x | -539.33% |
| 2012-12-31 | $12.53 Million | $-10.47 Million | -0.836x | -151.03% |
| 2011-12-31 | $8.46 Million | $13.85 Million | 1.638x | -- |
About GlycoMimetics Inc
GlycoMimetics, Inc. engages in the discovery and development of therapies for cancers and inflammatory diseases in the United States. The company was founded in 2003 and is based in Monrovia, Maryland.